We next sought to investigate the cytotoxic potential of our mRNA-based single-targeting (HER2 CAR, IL13Rα2 CAR, or EphA2 CAR) and multi-targeting (CARPool#2 and MVCAR#2) CAR T cells against patient-derived glioma cells. This evidence concerns the gene ERBB2 and central nervous system cancer.